Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar;96(10):e6301.
doi: 10.1097/MD.0000000000006301.

The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis

Xuefen Lei  1 , Feng Wang, Yang Ke, Dong Wei, Hou Gu, Zhixian Zhang, Lifeng Jiang, Li Lv, Jie Lin, Lin Wang
Affiliations
Meta-Analysis

The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis

Xuefen Lei et al. Medicine (Baltimore). 2017 Mar.

Erratum in

Abstract

Background: The survival of advanced gastric cancer (GC) is dismal, and effects of antiangiogenic agents remain inconclusive. The purpose of this study is to assess combination of chemotherapy with antiangiogenic therapy versus traditional chemotherapy.

Methods: To achieve the goal of scientific rigor, statistics from both referenced works and experiments were analyzed. We carefully searched for the referenced works by retrieving, as well as analyzing, literature databases for information on antiangiogenic therapy compared to other therapeutic approaches used to treat GC patients. Two groups were defined in the experiment: experimental and control groups. The experimental group was treated with antiangiogenic drug, and the control group was treated with standard chemotherapy or placebo.

Results: The study included a total of 3240 participants. Overall, there was significant improvement in overall survival (hazard ratio [HR] = 0.78, 95% confidence interval [CI]: 0.67-0.91, P = 0.002), progression-free survival (HR 0.65, 95% CI: 0.52-0.81, P = 0.0002), objective response rate (risk ratio [RR] = 1.58, 95% CI: 1.33-1.88, P < 0.00001), and disease control rate (RR 2.44, 95% CI: 1.57-3.78, P < 0.0001) in the group with antiangiogenic drug versus the group with standard chemotherapy or placebo. Moreover, this new treatment approach showed tolerable toxicity.

Conclusion: This study confirms the superior efficacy of combination therapy with antiangiogenic agents in comparison to traditional chemotherapy regimens for patients with GC. Moreover, this new treatment approach showed tolerable toxicity. This meta-analysis provides important information for clinicians who are interested in using antiangiogenic therapies to treat GC patients.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Select the relevant articles of process flowchart.
Figure 2
Figure 2
Evaluation of each study bias.
Figure 3
Figure 3
Forest plot and pooled HR & 95%CI for progression-free survival: Anti-angiogeneis agents of experimental versus control group.
Figure 4
Figure 4
Forest plot and pooled HR & 95%CI for Overall survival: Anti-angiogeneis agents of experimental versus control group.
Figure 5
Figure 5
Forest plot and pooled HR & 95%CI for objective response rate: Anti-angiogeneis agents of experimental versus control group.
Figure 6
Figure 6
Forest plot and pooled HR & 95%CI for disease control rate: Anti-angiogeneis agents of experimental versus control group.
Figure 7
Figure 7
Publication bias qualitative analysis: funnel plot includes the meta-analysis of all studies outcome. (A) Overall survival, (B) progression-free survival; (C) objective response rate; (D) disease control rate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Li XF, Tan YN, Cao Y, et al. A case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancer. Medicine (Baltimore) 2015;94:e1661. - PMC - PubMed
    1. Zhu B, Wu JR, Zhou XP. Retrospective comparison of trastuzumab plus cisplatin and trastuzumab plus capecitabine in elderly HER2-positive advanced gastric cancer patients. Medicine (Baltimore) 2015;94:e1428. - PMC - PubMed
    1. Tey J, Choo BA, Leong CN, et al. Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era. Medicine (Baltimore) 2014;93:e118. - PMC - PubMed
    1. Kim KH, Kim SH, Kim MC. How much progress has been made in minimally invasive surgery for gastric cancer in Korea?: a viewpoint from Korean prospective clinical trials. Medicine (Baltimore) 2014;93:e233. - PMC - PubMed
    1. Ma J, Yao S, Li XS, et al. Neoadjuvant therapy of DOF regimen plus bevacizumab can increase surgical resection rate in locally advanced gastric cancer: a randomized, controlled study. Medicine (Baltimore) 2015;94:e1489. - PMC - PubMed

MeSH terms

Substances